November 28, 2017 / 12:18 PM / 19 days ago

BRIEF-European Medicines Agency Validates Bristol-Myers's Type II Variation Application For Opdivo

Nov 28 (Reuters) - Bristol-Myers Squibb Co:

* EUROPEAN MEDICINES AGENCY VALIDATES BRISTOL-MYERS SQUIBB’S TYPE II VARIATION APPLICATION FOR OPDIVO (NIVOLUMAB) PLUS YERVOY (IPILIMUMAB) IN INTERMEDIATE- AND POOR-RISK PATIENTS WITH ADVANCED RENAL CELL CARCINOMA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below